Taizhou zone new hire Gu Yuexi is currently doing biology research. [Photo/WeChat account:weigg6666]
The Taizhou Medical High-tech Zone – also known as China Medical City, located in Taizhou city, in East China's Jiangsu province – is poised to boost the high-quality development of its big health industry, according to a guideline released by the provincial committee and government.
As a zone centered on the bio-pharmaceuticals industry, the Taizhou Medical High-tech Zone plans to seize policy opportunities presented by the integration of industry, the city and customers – and to promote Taizhou's big health industry on a larger scale and at a higher level.
Gu Yuexi, a talent with a doctorate degree and with more than 10 years' experience in basic biology research, was recruited by the zone as an urgently needed professional in June 2022.
He made the choice because the zone had many leading bio-pharmaceuticals enterprises, complete R&D conditions and strong policy support.
Besides the big health industry, the provincial government is also pivoting to support the innovation and development of vaccines, diagnostic reagents, veterinary biological products, special foods, Chinese medicine and other fields.
At present, the zone has formed a "3+2" industry supply chain. The scale of its pharmaceuticals industry reached 63.05 billion yuan ($9.32 million) in 2021, up 8.1 percent year-on-year.
Of that, the vaccine industry had the highest concentration and was the only national pilot for the concentrated development of the new vaccines and specific diagnostic reagents industry.